Tag - CymaBay


Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.